Prevalence of Fractures Among Men with Stage IV Prostate Cancer
Many of us believe that the risk developing bone fractures is more common in men who have stage 4 prostate cancer that has developed distant metastasis than those men with stage 4 prostate cancer that [...]
Data Links Bisphosphonates and Atrial Fibrillation (AF)
A large meta-analysis of nine studies showed that both oral and IV bisphosphonates were associated with a significantly increased risk of new-onset atrial-fibrillation (AF). The analysis also showed that the risk was greater with the [...]
CTCs As A Biomarker to Predict Survival in Men with Metastatic CRPC – Can We Be Triaged to Death?
Higher circulating tumor cell counts are associated with an increased risk of death. Men with metastatic castrate resistant prostate cancer don’t have a good biomarker to predict survival. According to a study published online ahead [...]
Teleconference on Prostate Cancer and Bone Health Tomorrow
Malecare Prostate Cancer Support will present a teleconference titled, "Bone Health and Prostate Cancer.” The conference is scheduled for Tuesday, March 25, 2014 at 6PM ET. The teleconference is available without cost and open to public [...]
Our Brothers Have Been Dealt a Blow by NICE- They Might Not Approve Xofigo
Officials from the National Institute for Health and Care Excellence (Nice) have made a preliminary decision not to recommend covering the drug radium-223 dichloride (Xofigo) for use for men with prostate cancer that has spread [...]
Duration of Response to Androgen Deprivation Therapy (ADT) and Efficacy of Secondary ADT, Docetaxel and Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
Men who become castrate resistant in less than 12 months from starting androgen deprivation therapy (ADT) were found to have poor efficacy with a 2nd line of ADT. However, the development of early castrate resistance [...]